December 6, 2021 5:37pm
The Biostage (BSTG) Chronicles: Monday closed +$021 to $3.21 with 6,466 shares traded after Friday closed flat with 0 shares traded – “buying and volume pump” is as active as ever. Finally, it’s been days … the website reflects the change in management – took them a while … most of it is “OLD” news regurgitated to look like it’s current news …
Pre-open indication results: 7 HITs, 2 MISS
Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?
If I have learned one thing as a former research analyst, venture and public markets investor to a journalist; it is that your life and your bank account are largely tied to your questioning of price targets.
The Dow closed UP +646.95 points (+1.87%); the S&P closed UP +53.24 points (+1.17%) while the Nasdaq closed UP +139.68 points (+0.93%)
Henry’omics:
indexes rallied to start to the week Monday, as investors shook off fears around the emerging threat of the omicron variant of Covid-19.
The Nasdaq was near session highs, up 0.9% but still below its 50-day moving average.
Volume on Nasdaq was lower compared to Friday.
Last week, the CBOE volatility index, the VIX fear gauge, Monday slowed at 27.70 after Friday’s high of 30.96 after Thursday’s 27.95 after Wednesday’s 31.12, Tuesday’s 27.19 and Monday’s 22.96.
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …
- Monday opened negative at 13 ups/21 downs and 1 acquired, flipped positive at the mid-day at 23/11, 1 flat and 1 acquired, ending with a positive close of 25/9 and 1 acquired;
- Friday opened negative at 0 ups/32 downs, 2 flats and 1 acquired, stayed negative at the mid-day at 0/33, 1 flat and 1 acquired, ending with a positive close of 1 up/31 downs, 2 flats and 1 acquired;
RegMed Investors’ (RMi) pre-open: “lean pickings. The stem, cell and gene therapy sector has sold off sharply in the past few weeks” … https://www.regmedinvestors.com/articles/12212
Pre-open indication results: 7 HITs: < Applied Genetic Technologies (AGTC +$0.04), BioLife Solutions (BLFS +$0.06), Mesoblast (MESO +$0.66), Solid Biosciences (SLDB +$0.07), Fate Therapeutics (FATE -$0.16), CRISPR Therapeutics (CRSP +$1.03), Cellectis SA (CLLS -$0.19) and 2 MISS < Pluristem (PSTI -$0.03), Biostage (BSTG +$0.21),
The Biostage (BSTG) Chronicles: Monday closed +$021 to $3.21 with 6,466 shares traded after Friday closed flat with 0 shares traded after Thursday closed up +$0.07 with 3,527 shares traded after Wednesday closed up +$0.95 with 2,590 shares traded after Tuesday closed down again -$0.02 with 2,143 shares traded after Monday closed down -$0.40 to $2.00 with 6,025 shares traded.
- New “interim” CEO and chairman with a personal investment.
- Finally, the website reflected the change in management – took them a while … most of it is “OLD” news regurgitated to look like it’s current news …
- My view, “the grifters are still running the company”
- NO clinical trial from a one (1) and 3/4-year-old IND and a negligence rejection of reimbursement in a terminal death suit.
- What’s there to invest in, the “Sword of Damocles” terminal death suit insurance claim rejection hanging over the companies non-going operations?
Key Metric - volume
Sector volume INCREASED with 8 of the 25-upside having higher than the 3-month average volume with LOW volume of 5 of 9-downside having higher than the 3-month average volume;
Outstanding Downside Volume:
- Bellicum Pharmaceuticals (BLCM) 945,125 K shares traded
Outstanding Upside Volume:
- Solid Biosciences (SLDB) with 3.129 m shares traded
- CRISPR Therapeutics (CRSP) with 2.45 m shares traded
The 52-week losers:
- XBI reached a 52-week low of $107.62
- SAGE Therapeutics (SAGE) reached a 52-week low of $36.13
- CRISPR Therapeutics (SAGE) reached a 52-week low of $67.13
- Fate Therapeutics (FATE) reached a 52-week low of $46.45
- Cellectis SA (CLLS) reached a 52-week low of $7.90
- Applied Genetic Technologies (AGTC) reached a 52-week low of $1.87
- Homology Medicine (FIXX) reached an all-time low of $4.44
Jumping with share pricing momentum (10 of 25):
- Alnylam Pharmaceuticals (ALNY +$5.64 after Friday’s -$11.9),
- Ultragenyx (RARE +$2.88 after Friday’s -$3.11),
- Vericel (VEL +$1.81),
- Regenxbio (RGNX +$1.22 after Friday’s -$1.05),
- Ionis Pharmaceuticals (IONS +$1.11 after Friday’s +$0.24),
- CRISPR Therapeutics (CRSP +$1.03 after Friday’s -$6.76),
- uniQure NV (QURE +$0.74),
- Global Blood Therapeutics (GBT +$0.71 after Friday’s -$1.45),
- Mesoblast (MESO +$0.66),
- Chinook therapeutics (KDNY +$0.66),
Hammered in today’s market (9 of 9):
- ReNeuron (RENE.L -$0.50),
- Intellia Therapeutics (NTLA -$0.27 after Friday’s -$8.92),
- Cellectis SA (CLLS -$0.19),
- Fate Therapeutics (FATE -$0.16 after Friday’s -$4.60),
- Bellicum Pharmaceuticals (BLCM -$0.09),
- Homology Medicine (FIXX -$0.06),
- Verastem VSTM -$0.040,
- Pluristem (PSTI -$0.030,
- Athersys (ATHX -$0.01),
Closing Flat:
- 1 - Stemline Therapeutics (STML) – acquired
Stats:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Monday the IBB closed down -201% and XBI closed up +0.15%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Monday was down -2.97 points or -9.68% at 27.70
December, the second month of Q4/21:
Monday (12/6) closed positive with 25 incliner, 9 decliners and 1 acquired
Friday closed negative with 1 incliner, 31 decliners, 2 flats and 1 acquired
Thursday closed positive with 26 incliners, 8 decliners and 1 acquired
Wednesday (12/1) closed negative with 4 incliners, 29 decliners, 1 flat and 1 acquired
The BOTTOM LINE: A good session, the oversold were recognized.
They have been few and far between; although tax selling is upon us!
In any case, I have continued to write … don’t ramp exposure at the current levels.
There's also nothing wrong with standing pat after reducing exposure earlier in the month.
Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
